Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

×

Message d'erreur

  • Notice : Undefined property: stdClass::$ds_changed dans eval() (ligne 16 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$ss_search_api_url dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice : Undefined property: stdClass::$tm_title dans eval() (ligne 20 dans /var/www/7/modules/php/php.module(80) : eval()'d code).

Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Mercredi, mai 17, 2023
Information
Tags: 
Biotechnology, Surgery, Health, Clinical Trials, Cardiology, Edwards, CE, Freedom, SVD, Guy's and St Thomas' NHS Foundation Trust, Calcification, Structural heart disease, Quality of life, Heart valve, Calcium, Cardiothoracic surgery, 103rd Ohio Infantry Regiment, Patient, American Association for Thoracic Surgery, Mitral valve, Physician, NHS foundation trust, IDE, Aortic stenosis, Safety, Pharmaceutical industry, Medical imaging
Geotags: 
UNITED KINGDOM, EUROPE, UNITED STATES
Organisation: 
EDWARDS LIFESCIENCES
Résumé
Key Points: 
  • Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer.
  • Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra RESILIA* transcatheter aortic heart valve.
  • The latest data from the COMMENCE aortic trial join a growing library of clinical studies in support of RESILIA tissue.
  • The trial is evaluating the safety and effectiveness of Edwards' bioprosthetic aortic valve with RESILIA tissue in patients ages 18 and older with diagnosed aortic valve disease and scheduled to undergo aortic valve replacement surgery.


Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented today at the 103rd annual meeting of the American Association for Thoracic Surgery.

SVD can be caused by a buildup of calcium that may impact long-term durability of bioprosthetic valves. Heart valves with RESILIA tissue are designed to address calcification challenges of conventional tissue valves, potentially allowing valves with RESILIA to last longer. The RESILIA tissue data from the COMMENCE aortic trial reported encouraging results with low rates of SVD (99.3% freedom from SVD), clinically stable gradients and freedom from reoperation (97.2%) through seven years.

"It is encouraging to see the strong clinical outcomes and excellent durability data from the seven-year data of the COMMENCE aortic trial on younger patients with a mean age of 65.1 years" said Gianluca Lucchese, Consultant Cardiac Surgeon, Guy’s and St Thomas' NHS Foundation Trust. "Valve durability keeps improving with latest innovative technologies. This is a significant progress as more and more younger and active patients undergo bioprosthetic aortic valve replacement."

Current technologies utilizing this novel tissue include the INSPIRIS RESILIA aortic valve, the KONECT RESILIA* aortic valved conduit, the MITRIS RESILIA* mitral valve and the SAPIEN 3 Ultra RESILIA* transcatheter aortic heart valve. In addition to its anti-calcification properties, RESILIA tissue also allows the valve to be stored under dry packaging conditions, facilitating ease of use in the operating room.

"Edwards Lifesciences is committed to addressing the needs of patients with structural heart disease and our RESILIA tissue technology is designed for enhanced durability, supporting patients' improved quality of life," said Larry Wood, Edwards' corporate vice president and group president, transcatheter aortic valve replacement and surgical structural heart. "The latest COMMENCE aortic trial data emphasizes the value of RESILIA tissue-based offerings in helping patients and their physicians with lifetime management of valve disease."

The latest data from the COMMENCE aortic trial join a growing library of clinical studies in support of RESILIA tissue.

The COMMENCE aortic trial is a prospective, non-randomized, multicenter, single-arm investigational device exemption (IDE) trial comprised of 689 patients at 27 clinical sites across the United States and Europe. The trial is evaluating the safety and effectiveness of Edwards' bioprosthetic aortic valve with RESILIA tissue in patients ages 18 and older with diagnosed aortic valve disease and scheduled to undergo aortic valve replacement surgery. Long-term follow-up data were collected in a subset of these patients and will continue to be evaluated through 10 years.

Gianluca Lucchese is a consultant to Edwards Lifesciences.

*At this time the following devices KONECT RESILIA, MITRIS RESILIA and the SAPIEN 3 Ultra RESILIA are not CE marked.

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit https://www.edwards.com/gb and follow us on LinkedIn and Twitter.

Edwards, Edwards Lifesciences, and the stylized E logo, COMMENCE, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS, MITRIS RESILIA, SAPIEN and RESILIA are trademarks and service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

# # #

Copyright: 
Copyright Business Wire 2023